Contents
- 1 The most common extranodal site of non-Hodgkin lymphoma (NHL) is
- 2 Not true of primary gastric lymphoma is
- 3 Most common presentation of primary gastric lymphoma is
- 4 All are true of diagnosis of primary gastric lymphoma except
- 5 Not true of MALT Gastric Lymphoma is
- 6 All are true of Diffuse large B-cell lymphomas (DLBCL) except
- 7 In short
The most common extranodal site of non-Hodgkin lymphoma (NHL) is
A. Stomach
B. Small intestine
C. Ileocecal regions
D. Jejunum
Not true of primary gastric lymphoma is
A. 90% of the PGL are of B-cell lineage
B. Mantle cell lymphoma express T cell markers
C. Campylobacter jejuni (C jejuni) is as an important organism implicated in the pathogenesis of MALT lymphoma
D. Biopsy samples taken during an esophagogastroduodenoscopy (EGD) is the gold standard for diagnosis of PGL
Most common presentation of primary gastric lymphoma is
A. Atypical ulcers
B. Obstruction
C. Gastric wall thickening
D. Lesion with bleeding
All are true of diagnosis of primary gastric lymphoma except
A. MRI can also be used to evaluate PGL
B. F-FDG-PET/TC is considered adequate diagnostic technique
C. Esophagogastroduodenoscopy( EUS) tends to overstage residual disease
D. CT scan can detect gastric wall thickening in 85% of cases
Not true of MALT Gastric Lymphoma is
A. There is an association between H pylori infection and the presence of MALT.
B. T cells and macrophages play an important role in MALT lymphomagenesis
C. It is an indolent marginal zone B-cell lymphoma and a low-grade neoplasia
D. Gastric MALT can be easily diagnosed in punch biopsy
All are true of Diffuse large B-cell lymphomas (DLBCL) except
A. Gastrectomy remains the mainstay of therapy
B. The disease is usually aggressive, and the diagnosis is commonly made by biopsy of a suspicious lymph node
C. PET CT is a standard initial imaging study
D. High lactate dehydrogenase (LDH) is related to bad prognosis
In short
The treatment of DLBCL-PGL consists of anthracycline-based chemoimmunotherapy. The current recommendation is to treat with R-CHOP every 14 to 21 days for 6 to 8 cycles.
The immunohistochemical (IHC) algorithm developed by Hans and Tally is the most widely used to determine cells of origin.
DLBCL is an aggressive but curable disease for most patients
